In EDS ansehen

PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences

Gespeichert in:
Bibliographische Detailangaben
Titel: PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences
Autoren: Sophie C. Kunte, Vera Wenter, Johannes Toms, Simon Lindner, Marcus Unterrainer, Friederike Eilsberger, Klaus Jurkschat, Carmen Wängler, Björn Wängler, Ralf Schirrmacher, Maximilian W. Tiling, Gabriel T. Sheikh, Dirk Mehrens, Matthias Brendel, Johannes Rübenthaler, Christoph J. Auernhammer, Christine Spitzweg, Lena M. Unterrainer, Adrien Holzgreve
Quelle: Eur J Nucl Med Mol Imaging
European journal of nuclear medicine and molecular imaging 52(3), 900-912 (2025). doi:10.1007/s00259-024-06944-y
European journal of nuclear medicine, vol 52, iss 3
Verlagsinformationen: Springer Science and Business Media LLC, 2024.
Publikationsjahr: 2024
Schlagwörter: Male, Adult, Fluorine Radioisotopes, Papillary thyroid carcinoma (PTC), Follicular thyroid carcinoma (FTC), Medullary thyroid carcinoma (MTC), Serum tumor marker, Positron Emission Tomography Computed Tomography/methods [MeSH], Receptors, Somatostatin/metabolism [MeSH] [Female [MeSH], Aged [MeSH], Adult [MeSH], Humans [MeSH], Somatostatin receptor (SSTR), Middle Aged [MeSH], Carcinoma, Neuroendocrine/metabolism [MeSH], Thyroid Neoplasms/pathology [MeSH], Original Article, Thyroid Neoplasms/diagnostic imaging [MeSH], Thyroid Neoplasms/metabolism [MeSH], Male [MeSH], Carcinoma, Neuroendocrine/diagnostic imaging [MeSH], Carcinoma, Neuroendocrine/pathology [MeSH], Differentiated thyroid carcinoma (DTC), (4–6)], Positron Emission Tomography Computed Tomography, Receptors, Humans, ddc:610, Thyroid Neoplasms, Receptors, Somatostatin, (4–6): Medullary thyroid carcinoma (MTC), Aged, Carcinoma, diagnostic imaging [Carcinoma, Neuroendocrine], Middle Aged, Carcinoma, Neuroendocrine, diagnostic imaging [Thyroid Neoplasms], Neuroendocrine, Female, Somatostatin, metabolism [Thyroid Neoplasms], metabolism [Receptors, Somatostatin], Medullary thyroid carcinoma (MTC) [(4–6)]
Beschreibung: Purpose The novel 18F-labeled somatostatin receptor (SSTR)-directed radiotracer [18F]SiTATE demonstrated promising results for the imaging of various SSTR-expressing tumor types. Although thyroid carcinomas (TC) express SSTR, data on [18F]SiTATE PET/CT imaging in TC are lacking. This study explores the use of [18F]SiTATE PET/CT in a patient cohort with histologically proven TC. Methods As part of a prospective observational study at a single tertiary cancer center, 21 patients with TC (10 medullary (MTC) and 11 differentiated (DTC)) who underwent at least one [18F]SiTATE PET/CT were included (37 scans in total). Mean SUVmax and SUVmean of tumoral lesions, mean total-tumor-volume (TTV), and whole-body (WB)-SUVmax and WB-SUVmean on PET with their standard deviations (SDs) were determined. PET parameters were correlated to clinical parameters including tumor marker levels (thyroglobulin for DTC, calcitonin for MTC). Results 89 lesions were included in the analysis. Metastases were localized in the bone, lymph nodes, lung, soft tissue, and thyroid bed. Osseous (31 lesions; SUVmax 8.6 ± 8.0; SUVmean 5.8 ± 5.4) and nodal (37 lesions; SUVmax 8.7 ± 7.8; SUVmean 5.7 ± 5.4) metastases showed the highest uptake. The MTC disease burden on PET significantly correlated with the calcitonin tumor marker level (e.g., TTV: r = 0.771, r2 = 0.594, p = 0.002). For DTC, no such correlation was present. Conclusion Our data demonstrate high feasibility of [18F]SiTATE PET/CT in a small cohort of patients with MTC and DTC. The use of [18F]SiTATE may overcome logistical disadvantages of 68Ga-based tracers and facilitate SSTR-targeted PET/CT imaging of thyroid carcinoma.
Publikationsart: Article
Other literature type
Dateibeschreibung: application/pdf
Sprache: English
ISSN: 1619-7089
1619-7070
DOI: 10.1007/s00259-024-06944-y
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39404789
https://pub.dzne.de/record/276155
https://repository.publisso.de/resource/frl:6518833
https://epub.ub.uni-muenchen.de/123275/
https://escholarship.org/content/qt009034dj/qt009034dj.pdf
https://escholarship.org/uc/item/009034dj
Rights: CC BY
Dokumentencode: edsair.doi.dedup.....d80639f4f0a7ae0c2507f83fc8a71bbc
Datenbank: OpenAIRE
Beschreibung
Abstract:Purpose The novel 18F-labeled somatostatin receptor (SSTR)-directed radiotracer [18F]SiTATE demonstrated promising results for the imaging of various SSTR-expressing tumor types. Although thyroid carcinomas (TC) express SSTR, data on [18F]SiTATE PET/CT imaging in TC are lacking. This study explores the use of [18F]SiTATE PET/CT in a patient cohort with histologically proven TC. Methods As part of a prospective observational study at a single tertiary cancer center, 21 patients with TC (10 medullary (MTC) and 11 differentiated (DTC)) who underwent at least one [18F]SiTATE PET/CT were included (37 scans in total). Mean SUVmax and SUVmean of tumoral lesions, mean total-tumor-volume (TTV), and whole-body (WB)-SUVmax and WB-SUVmean on PET with their standard deviations (SDs) were determined. PET parameters were correlated to clinical parameters including tumor marker levels (thyroglobulin for DTC, calcitonin for MTC). Results 89 lesions were included in the analysis. Metastases were localized in the bone, lymph nodes, lung, soft tissue, and thyroid bed. Osseous (31 lesions; SUVmax 8.6 ± 8.0; SUVmean 5.8 ± 5.4) and nodal (37 lesions; SUVmax 8.7 ± 7.8; SUVmean 5.7 ± 5.4) metastases showed the highest uptake. The MTC disease burden on PET significantly correlated with the calcitonin tumor marker level (e.g., TTV: r = 0.771, r2 = 0.594, p = 0.002). For DTC, no such correlation was present. Conclusion Our data demonstrate high feasibility of [18F]SiTATE PET/CT in a small cohort of patients with MTC and DTC. The use of [18F]SiTATE may overcome logistical disadvantages of 68Ga-based tracers and facilitate SSTR-targeted PET/CT imaging of thyroid carcinoma.
ISSN:16197089
16197070
DOI:10.1007/s00259-024-06944-y